In the past week, APTO stock has gone down by -17.76%, with a monthly decline of -31.47% and a quarterly plunge of -55.68%. The volatility ratio for the week is 8.48%, and the volatility levels for the last 30 days are 8.68% for Aptose Biosciences Inc The simple moving average for the last 20 days is -19.62% for APTO stock, with a simple moving average of -69.84% for the last 200 days.
Is It Worth Investing in Aptose Biosciences Inc (NASDAQ: APTO) Right Now?
The stock has a 36-month beta value of 0.87. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APTO is 56.47M, and at present, short sellers hold a 2.32% of that float. On January 29, 2025, the average trading volume of APTO was 6.84M shares.
APTO) stock’s latest price update
Aptose Biosciences Inc (NASDAQ: APTO)’s stock price has plunge by -10.43relation to previous closing price of 0.19. Nevertheless, the company has seen a -17.76% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-09 that SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced dosing the first set of patients in the TUSCANY Phase 1/2 study with tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA) as a frontline triple drug combination (triplet) therapy for patients newly diagnosed with acute myeloid leukemia, or AML. Tuspetinib based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated.
Analysts’ Opinion of APTO
Many brokerage firms have already submitted their reports for APTO stocks, with Cantor Fitzgerald repeating the rating for APTO by listing it as a “Overweight.” The predicted price for APTO in the upcoming period, according to Cantor Fitzgerald is $10 based on the research report published on October 19, 2020 of the previous year 2020.
Alliance Global Partners, on the other hand, stated in their research note that they expect to see APTO reach a price target of $12. The rating they have provided for APTO stocks is “Buy” according to the report published on September 22nd, 2020.
Maxim Group gave a rating of “Buy” to APTO, setting the target price at $16 in the report published on February 20th of the previous year.
APTO Trading at -22.35% from the 50-Day Moving Average
After a stumble in the market that brought APTO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.19% of loss for the given period.
Volatility was left at 8.68%, however, over the last 30 days, the volatility rate increased by 8.48%, as shares sank -29.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -55.31% lower at present.
During the last 5 trading sessions, APTO fell by -18.62%, which changed the moving average for the period of 200-days by -87.68% in comparison to the 20-day moving average, which settled at $0.2136. In addition, Aptose Biosciences Inc saw -23.75% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APTO starting from Rice William G., who purchase 100,000 shares at the price of $0.20 back on Nov 25 ’24. After this action, Rice William G. now owns 613,252 shares of Aptose Biosciences Inc, valued at $20,000 using the latest closing price.
Stock Fundamentals for APTO
Current profitability levels for the company are sitting at:
- -51.23 for the present operating margin
- 0.52 for the gross margin
The net margin for Aptose Biosciences Inc stands at -50.67. The total capital return value is set at -31.16. Equity return is now at value -694.13, with -225.12 for asset returns.
Based on Aptose Biosciences Inc (APTO), the company’s capital structure generated 6.76 points at debt to capital in total, while cash flow to debt ratio is standing at -3.49. The debt to equity ratio resting at -1.17. The interest coverage ratio of the stock is -66.22.
Currently, EBITDA for the company is -52.27 million with net debt to EBITDA at -0.3. When we switch over and look at the enterprise to sales, we see a ratio of 29.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.05.
Conclusion
To sum up, Aptose Biosciences Inc (APTO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
